Status:
WITHDRAWN
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Non Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelia...
Eligibility Criteria
Inclusion
- Japanese patients with non small cell lung cancer or epithelial ovarian cancer
- Must be suitable for treatment with carboplatin and paclitaxel
- Relatively good overall health other than cancer
Exclusion
- Poor bone marrow function (not producing enough blood cells).
- Poor liver or kidney function.
- Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01000896
Start Date
January 1 2010
End Date
March 1 2011
Last Update
February 4 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Matsuyama, Ehime, Japan
2
Research Site
Fukuoka, Fukuoka, Japan